De-risking Drug Development: Key Chemistry, Manufacturing, and Controls (CMC) and Physiologically Based Pharmacokinetic (PBPK) Approaches in Early Development
November 22, 2024 In drug development, early strategic planning is crucial to minimizing risks, optimizing…
CertaraNovember 22, 2024
Towards Predicting Individual Cognitive Trajectories in Alzheimer’s Disease using Quantitative Systems Pharmacology
About Functional readouts in Alzheimer's Disease is highly variable due to different comedications, genotypes, amyloid-…
CertaraNovember 22, 2024
Effects of Anti-Amyloid Treatment on Tau Biomarkers and Functional Outcome
About There are major unaddressed issues in Alzheimer's Disease clinical practice such as: Identifying accessible…
CertaraNovember 22, 2024
A Mechanistic PK/PD Model for First-in-Human Dosing of a Tetraspecific Antibody (MDX2001) for the Treatment of Advanced Solid Tumors
MDX2001 is a tetraspecific T cell engager that binds CD3 and CD28 on T cells…
CertaraNovember 22, 2024
